Skip to main content
2022 Guide to Patient Support Services

Blueprint Medicines

2022 Oncology Guide to Patient Support Services

Blueprint Medicines Support Services


Blueprint Medicines offers the YourBlueprint patient support program to provide appropriate information and assistance to patients taking Ayvakit (Table).


YourBlueprint patient support program offers a QuickStart Program, Coverage Interruption Program, Ayvakit Dose Exchange Program, Co-pay Assistance Program, Patient Assistance Program, as well as a team of case managers, reimbursement specialists, and specialty pharmacy liaisons to assist your patients access treatment.

QuickStart Program

This program offers a temporary no-cost 15-day supply of medication in the event of a coverage-related delay. Patients may be eligible if they:

  • Are new to Ayvakit treatment
  • Have private/commercial or government insurance and are experiencing delays in coverage
  • Are enrolled in YourBlueprint.

Coverage Interruption Program

This program offers a no-cost 15-day supply of medication to patients already on therapy who face a temporary interruption in insurance coverage.

Ayvakit Dose Exchange Program

This program allows patients who have a change in their dose of Ayvakit to exchange remaining medication for the new dose.

Co-pay Assistance Program

Patients may be eligible for the Co-pay Assistance Program if they have commercial insurance with coverage for their prescription.

Patient Assistance Program

Patients may be eligible for the Patient Assistance Program if they:

  • Are uninsured or underinsured
  • Have a valid prescription for Ayvakit
  • Reside in the United States or a US territory
  • Meet certain financial and eligibility criteria.

Click here to learn more or to enroll your patient in YourBlueprint, or call 888-258-7768.

TABLE Blueprint Oncology Drug

Patient support programs

Ayvakit (avapritinib) tablets
Treatment of adults with unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations; treatment of adult patients with advanced systemic mastocytosis to include aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast-cell leukemia
Patient support programs

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"